Aspirin/antiplatelet agent use improves disease-free survival and reduces the risk of distant metastases in Stage II and III triple-negative breast cancer patients

MLA

Barbara Haley, et al. “Aspirin/Antiplatelet Agent Use Improves Disease-Free Survival and Reduces the Risk of Distant Metastases in Stage II and III Triple-Negative Breast Cancer Patients.” Breast Cancer Research and Treatment, vol. 161, Dec. 2016, pp. 463–71. EBSCOhost, https://doi.org/10.1007/s10549-016-4081-8.

APA

Barbara Haley, Aeisha Rivers, Jingsheng Yan, Rachel Wooldridge, A.S. Rahimi, Xian Jin Xie, D. W Nathan Kim, Ann Spangler, Jean Shiao, Roshni Rao, Deborah Farr, Kimberly Thomas, M. DaSilva, & Marilyn Leitch. (2016). Aspirin/antiplatelet agent use improves disease-free survival and reduces the risk of distant metastases in Stage II and III triple-negative breast cancer patients. Breast Cancer Research and Treatment, 161, 463–471. https://doi.org/10.1007/s10549-016-4081-8

Chicago

Barbara Haley, Aeisha Rivers, Jingsheng Yan, Rachel Wooldridge, A.S. Rahimi, Xian Jin Xie, D. W Nathan Kim, et al. 2016. “Aspirin/Antiplatelet Agent Use Improves Disease-Free Survival and Reduces the Risk of Distant Metastases in Stage II and III Triple-Negative Breast Cancer Patients.” Breast Cancer Research and Treatment 161 (December): 463–71. doi:10.1007/s10549-016-4081-8.